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Secondary chronic venous disorders (CVD) usually follow an episode of acute deep venous thrombosis (DVT). Most
occluded venous segments recanalize over the first 6 to 12 months after an episode of acute DVT, leading to chronic
luminal changes and a combination of partial obstruction and reflux. Such morphological changes produce venous
hypertension with the highest levels of ambulatory venous pressure occurring in patients with combined outflow
obstruction and distal reflux. The clinical manifestations of secondary CVD, including pain, venous claudication, edema,
skin changes, and ulceration are commonly referred to as the post-thrombotic syndrome. Such sequelae are best avoided
by early and aggressive treatment of proximal DVT.
The diagnostic evaluation of secondary CVD is similar to primary CVD and is based upon duplex ultrasound. However,
the definition of hemodynamically significant venous stenosis remains obscure and there are no reliable tests to confirm
the presence of such lesions. Diagnosis depends more on anatomic rather than hemodynamic criteria, and IVUS is
superior to venography in estimating the morphological degree and extent of iliac vein stenosis.
The fundamental role of compression in the treatment of CVD is well recognized. Compliance with compression is
essential to heal ulcers and minimize recurrence. The efficacy of various adjuncts to ulcer treatment, including complex
wound dressings and medications have been variable. Although superficial venous surgery has not been demonstrated to
improve ulcer healing rates, it does decrease ulcer recurrence. Deep venous valve reconstruction is performed in only a few
specialized centers, and the results are better for primary than for secondary CVD. Treatment of incompetent perforating
veins remains controversial. Although artificial venous valves are promising, most early experimental models have failed.
With respect to venous obstruction, iliocaval angioplasty and stenting has emerged as the primary treatment for proximal
iliofemoral venous obstruction with surgical bypass assuming a secondary role. ( J Vasc Surg 2007;46:68S-83S.)INTRODUCTION
The manifestations of chronic venous insufficiency may
be either primary or secondary in etiology. Primary venous
disorders are not associated with identifiable etiologic
mechanisms of venous dysfunction. In contrast, secondary
venous disorders result from an anteceded event, usually an
episode of acute deep venous thrombosis (DVT). Although
reflux alone is responsible for primary chronic venous in-
sufficiency (CVI), secondary CVI most often results from a
combination of obstruction and reflux. When developing
after an episode of DVT, manifestations of pain, edema,
From the Department of Surgery, University of Washington School of
Medicinea; Straub Foundationb; University College London Medical
Schoolc; Indiana University Medical Schoold; Department of Veteran’s
Affairse; Mayo Clinicf; Oregon Health Sciences Universityg; River Oaks
Hospitalh; New England Medical Centeri; and Department of Dermatol-
ogy, University of Viennaj.
Competition of interest: none
Correspondence: Mark H. Meissner, MD, Department of Surgery, Box
356410, University of Washington Medical Center, 1589 NE Pacific
Street, Seattle, WA 98195 (e-mail: meissner@u.washington.edu).
0741-5214/$32.00
Copyright © 2007 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2007.08.048
68Sskin changes and ulceration are commonly referred to as the
post-thrombotic syndrome.
Cutaneous ulceration due to CVI has been known for
over three and a half millennia. Aescalapius established care
centers as early as 1500 BC; although he treated venous
ulcers successfully, the details were largely ignored.1 In
400BC, Hippocrates, who himself had a leg ulcer, said, “In
the case of an ulcer, it is not expedient to stand, especially if
the ulcer be situated on the leg.”2 Compression was used
throughout the middle ages, and later by Richard Wise-
man, the 17th century Sergeant Surgeon to Charles II.3
John Gay pointed out in 1866 that skin changes and leg
ulcers were associated with post-thrombotic disease of the
deep veins. This concept was reiterated by Homans who
underlined the importance of venous stasis.
The Swedish phlebologist Gunnar Bauer first recog-
nized destruction of the deep venous valves as the cause of
post-thrombotic disease. Using descending transfemoral
venography, Bauer showed that most deep veins recana-
lized after DVT and that the valves were destroyed during
this process. He differentiated these findings from those of
primary CVI, noting that deep venous reflux identified on
descending venography was not caused by previous throm-
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the prevention and treatment of DVT, Bauer’s suggested
that the best way to avoid the post-thrombotic syndrome
was by immediate and aggressive treatment of acute throm-
bosis.
Once developed, venous leg ulcers are often a disabling
condition with significant chronicity. Nearly one half of
affected limbs suffer a recurrence within a decade. The
direct costs of ulcer treatment have been estimated to be
$2500 per month in the United States and approximately
1% of the national healthcare budget in other industrialized
countries.5 Any treatment modality that increases the pro-
portion of healed ulcers and speeds the rate of healing will
both reduce cost and decrease patient suffering.
DIAGNOSIS OF SECONDARY CHRONIC
VENOUS INSUFFICIENCY
Treatment should always be directed towards improv-
ing pathophysiology and, as described in the diagnosis and
hemodynamics section of this supplement, characterization
of the underlying anatomy and physiology is crucial for
successful therapy. Although the trophic and ulcerative
changes at the ankle may be identical, the underlying
pathophysiology and anatomy may be vastly different be-
tween limbs.6 The pathophysiology is often complex, with
a combination of venous reflux and obstruction, endothe-
lial dysfunction, deranged lymphatic function, and associ-
ated arterial occlusive disease, joint disorders, metabolic
disturbances, and other pathology contributing to the clin-
ical presentation. About 30% of leg ulcers are not of venous
origin and a “venous leg ulcer” should only be diagnosed if
major venous disturbances are both clearly demonstrated
and primarily responsible for the clinical presentation.
The history and clinical features are often misleading
and may not differentiate venous ulcers from other etiolo-
gies. The differential diagnosis must include arterial occlu-
sive disease; small vessel diseases such as vasculitis; hemato-
logical disorders like spherocytosis, sickle cell anemia,
cryoglobulinemia, and thrombocytosis; traumatic and self-
inflicted ulcers; ulcerated tumors like basal cell carcinoma;
infections caused by acid fast bacilli (Buruli-ulcer), fungi, or
protozoa; neuropathic ulcers; and others, like pyoderma
gangrenosum. The diagnosis in such cases can only be
made by specialized testing that may include bacteriologic
investigation and biopsies. Although it is not clear if they
are causative or an epiphenomenon, coagulation defects
have been described in 41% of patients with leg ulcers.7
However, this finding does suggests that many patients
with venous leg ulcers have unsuspected post-thrombotic
disease.
Evaluation of the patient with a suspected venous leg
ulcer should include duplex ultrasonography to identify
reflux in the superficial, deep, and perforating veins as well
as obstruction of the deep veins. Plethysmography, venous
pressure measurement, and venography may also be useful,
especially in patients being considered for surgery. Any
detected pathology should be classified using the CEAP
classification, which may guide further therapy.8 Measure-ment of the ankle-brachial index (ABI) by Doppler ultra-
sonography is essential in excluding arterial occlusive dis-
ease, which may be present in 20% of patients and is
required before initiating compression therapy. In measur-
ing the ankle pressure, the cuff should be placed on the
distal leg, even when there are ulcers in the region, and not
over the calf as occasionally recommended.
Early diagnosis and treatment is essential to rapid ulcer
healing. Lack of improvement over a 4-week period re-
quires re-evaluation of the diagnosis and consideration of a
biopsy to exclude either an ulcerated malignancy or malig-
nant transformation of the ulcer.
NONOPERATIVE TREATMENT OF CHRONIC
VENOUS INSUFFICIENCY
General recommendations
General measures in the treatment of chronic venous
insufficiency include leg elevation, which reduces venous
hypertension. Weight reduction, walking exercise, and
physical therapy to improve ankle joint mobility may also be
important. Systemic conditions affecting wound healing
and edema (diabetes mellitus, immunosuppression, malnu-
trition, congestive heart failure) should be optimally man-
aged.
Compression therapy
The fundamental role of compression in the treatment
of chronic venous insufficiency is well recognized and has
been validated by randomized controlled trials (RCTs).9,10
Compression can be achieved with a variety of techniques
and devices and is sufficient to heal the majority of venous
ulcers. Healing, however, can be prolonged and ulcer re-
currence remains a major problem. Patients must under-
stand that they have a chronic disease that can be managed
but not necessarily cured. Compliance with treatment is
essential to heal ulcers and minimize recurrence.11
The presence of chronic venous disease must be defin-
itively established prior to beginning compression therapy.
Arterial occlusive disease is a contraindication to conven-
tional high-pressure compression treatment. This is espe-
cially true for patients with an ABI  0.5 and with the use
of elastic, long stretch material. However, inelastic ban-
dages, applied with a resting pressure of less than 20 mm
Hg and used in conjunction with active exercise, will re-
duce edema and increase arterial flow similar to the use of
intermittent pneumatic compression.12
The exact mechanism by which compression improves
the symptoms of CVI and heals ulceration is unknown.
Although most experimental studies have been performed
using insufficient compression, high-pressure bandages do
reduce venous reflux and improve calf muscle pump func-
tion.13-15 Improvements in skin and subcutaneous micro-
circulation and direct effects on subcutaneous pressure have
also been hypothesized. A compression induced increase in
subcutaneous tissue pressure may counteract transcapillary
Starling forces, thereby decreasing edema.16,17 Edema re-
duction may also improve local metabolism by enhancing
3;32(
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tissues. Finally, cytokines, such as vascular endothelial
growth factor (VEGF) and tumor necrosis factor- (TNF-
), have been demonstrated to decrease with compression
therapy and this correlated with healing of the ulcer.18
Gradient elastic compression stockings are the most
commonly utilized compression devices. They are available
in various compositions, strengths, and lengths, andmay be
customized as necessary. For ulcers situated behind the
inner ankle or over flat parts of the leg, pads may be used to
increase local pressure.
Most compression hosiery manufacturers provide a
pressure range (mm Hg) based on in vitro measurements,
which may differ between manufacturers, and are not
strictly comparable.19 Compression classes are often pro-
vided by the manufacturer as a substitute for pressure range
(mmHg). Such classes also vary according to measurement
techniques and national regulations and are not compara-
ble. Stiffness, which is defined by the increase of pressure
created by an increase of the transverse stretch of the
stocking, is not regularly declared by manufacturers.
Guidelines for the appropriate use of compression stock-
ings are shown in Table I.20 The role of elastic compression
stockings in ulcer healing has been clearly validated.21,22
Among 113 patients with venous ulcers, healing occurred in
93% of those treatedwith 30 to 40mmHgbelow-knee elastic
compression stockings. Compliance with therapy was crucial.
Ulcer healing occurred in 97% of complaint patients in com-
parisonwith 55% of noncompliant patients. Themean time to
achieve healing was 5 months. Ulcer recurrence was 29% at 5
Table I. Indications for medical compression stockings
Indication
Compression pr
10-20 20-30
Chronic venous disorders
C0s 1st choice If necessary
C1s 1st choice If necessary
C2 1st choice If necessary
C3 If possible 1st choice If
C4 1st choice If
C5 If possible 1s
C6 1s
After procedures If possible 1s
Venous thromboembolism
Prevention 1st choice
Therapy 1s
Post-thrombotic syndrome
Prevention 1st choice If
Therapy If possible 1s
Adapted from Partsch, H. Evidence-based compression therapy. VASA 200years in compliant patients and 100% at 3 years in noncompli-ant patients.17 The prophylactic use of compression therapy in
patientswith previous venous ulcers has been shown tobe cost
effective.23
Elastic compression therapy also improves quality of life
in CVI patients. In a prospective study, 112 patients with
CVI completed a questionnaire assessing swelling, pain,
skin discoloration, cosmesis, activity tolerance, depression,
and sleep patterns. Patients were then treated with 30- to
40-mm Hg elastic compression stockings. There was over-
all improvement in symptom severity scores following 1
month of treatment. Further improvements were noted at
16 months.22
Many patients are initially intolerant of compression
over an ulcer. Patients should initially wear stockings only
as long as they are easily tolerated, gradually increasing the
time they are worn with the goal of wearing stockings
whenever ambulating. Compliance may also be improved
by initially fitting patients with lower-pressure stockings
and progressing to higher-strength stockings. Commercial
devices, such as silk inner toe liners, zippered stockings, and
metal fitting aids, are available to assist in the application of
elastic stockings.
Non-elastic or short stretch material may provide some
hemodynamic benefits over compression stockings. High
interface pressure compression narrows the veins even in
the standing position, and rigid, non-elastic or short stretch
material is able to intermittently occlude the veins during
muscle systole, reducing ambulatory venous pressure.24
Elastic compression stockings, which may have much lower
resting pressures and give way during muscle contraction,
cannot achieve these effects. Non-yielding materials have
(mm Hg)
Duration30-40 40
Symptomatic
Symptomatic
Symptomatic
ssary Symptomatic
ssary Routine
ice If necessary Always in deep CVD
ice or bandages Until healing
ice If necessary Variable
At risk
ice or bandages If necessary 4 wks
ssary 1 y after DVT
ice If necessary Indefinite
Suppl 63).20essure
nece
nece
t cho
t cho
t cho
t cho
nece
t choeffects similar to intermittent pneumatic compression dur-
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inflammatory, anticoagulant, and vasoactive mediators.25
These effects may account for the improved healing rates
attributed to multilayer high-pressure bandages.10
Unna’s boot is a compression bandage that has been
historically used to treat venous ulcers. The Unna boot is
classically a three-layer dressing, requiring application by
trained personnel. A rolled gauze bandage impregnated
with calamine, zinc oxide, glycerin, sorbitol, gelatin, and
magnesium aluminum silicate is first applied with graded
compression from the forefoot to just below the knee. A
4-inch-wide continuous gauze dressing is then applied,
followed by an outer elastic wrap, applied with graded
compression. Rigidity of the bandage after drying may
aid in decreasing edema. Unna boots are changed week-
ly; sooner if there is excessive ulcer drainage. The ban-
dage requires minimal patient involvement and provides
continuous compression and topical therapy. Potential
disadvantages are that it can be labor intensive, the
degree of compression is operator-dependent, the ban-
dage may be uncomfortable, and the ulcer cannot be
monitored. Patients may also occasionally develop a
contact dermatitis requiring discontinuation of therapy.
However, the technique is effective in achieving ulcer
healing. In a 15-year review of 998 patients with one or
more venous ulcers treated with Unna’s dressings, 73%
of ulcers healed in patients who returned for more than
one treatment. The median time to healing for individual
ulcers was 9 weeks.26
Other forms of ambulatory compression include mul-
tilayered dressings and compressive orthoses.27 Potential
advantages of multilayered dressings include maintenance
of compression for a longer period of time, more even
distribution of compression, and better absorption of
wound exudate. However, the efficacy of multilayered
dressings still depends on application technique. A com-
mercially available leg orthosis, consisting of multiple ad-
justable loop-and-hook closure compression bands, pro-
vides compression similar to Unna’s boot and can be
applied daily by the patient.27 In comparison with elastic
bandages, at least one recent study28 demonstrated supe-
rior ulcer healing with such devices.
Intermittent pneumatic compression pumps may also
be a useful adjunct in ulcer healing.29,30 Such supplemen-
tary compression may be especially useful in patients with
restricted walking ability and in those with an arterial
component to their ulcer. It is well established that venous
blood flow velocities are increased with intermittent pneu-
matic compression (IPC). In addition to the physical stim-
ulation of venous return,31,32 hematological and endothe-
lial cell stimulation has been documented. Increased
endogenous fibrinolysis,33 reduced intravascular coagula-
tion,34 and stimulation of at least three forms of nitric oxide
synthase (eNOS, iNOS, and nNOS) has been demon-
strated.35,36 Increased shear stress is llikely responsible for
most of these biomarker changes.25Wound dressings, skin substitutes and other
adjuvants to compression
Practice guidelines have recommended that simple
nonadherent wound dressing combined with compression
bandages be used in treating chronic venous ulcers.37
However, more complex or “modern dressings” have been
developed and recommended by some. These include both
the semi-occlusive and biologic dressings. The degree of
water vapor transmission distinguishes nonocclusive from
semi-occlusive dressings. Winter38 has shown that dress-
ings promoting a moist, warm healing environment (semi-
occlusive wounds), had a 40% increased epithelialization
rate in comparison with nonocclusive dressings.
Semi-occlusive dressings vary in their ability to reduce
water vapor transmission and other desirable characteris-
tics.39 Film dressings, composed of transparent, adherent
polyurethane, protect and insulate the wound while pro-
moting autolytic debridement of the eschar. Since this
dressing type does not absorb wound drainage, maceration
of the surrounding skin can occur. Hydrocolloid dressings
have a water impermeable outer layer of polyurethane and
an inner hydrocolloid layer that both debrides and protects
the wound, while facilitating absorption of wound drain-
age. Semitransparent and nonadherent hydrogel dressings
are usually provided in sheets and contain insoluble poly-
mers that absorb water. Foam dressings can absorb signif-
icant quantities of exudate from the wound and are com-
posed of silastic or polyurethane foam. Finally, alginate
dressings (eg, sodium alginate) possess the maximal ca-
pacity of this dressing class for handling copious wound
drainage.
The second major class of modern wound dressings has
been termed biologic, because they either directly provide
growth factors or indirectly stimulate growth factors within
the wound (growth factor group) and accelerate healing.
“Bioengineered” skin ranges in composition from acellular
to living skin substitutes. Skin substitutes not only provide
wound coverage, but also promote wound healing by
growth factors. Apligraf is a commercially available, bilay-
ered living skin construct that closely approximates human
skin. It contains a stratum corneum and an epidermis with
keratinocytes overlying a dermis of fibroblasts in a collagen
matrix. It is supplied as a disk of living tissue on a gel
medium and must be used within 5 days of release from the
manufacturer.40 How skin substitutes aid in healing venous
ulcers is uncertain, although it is likely that they are delivery
vehicles for important growth factors.
Evaluation of adjuvants to compression. Despite
arguments for or against such an approach, the advantages
of “modern dressings” should be proven in randomized
clinical trials (RCTs), where the risk of error is low and the
statistical strength is great. Level I RCTs not only provide
scientific validation of a treatment option, but also strongly
influence reimbursement by Center forMedicare andMed-
icaid Services (CMS) and other third party payors. Two
previous major systematic reviews, completing their review
period in 1997, concluded that “methodological weak-
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particular, they found no difference over standard control
dressings for hydrocolloids, foam/films, and finally some of
the “modern” dressings.
As part of a Federal agency-sponsored assessment of
wound care, all RCTs on wound care published between
1997 and September 2005 were recently reviewed.39 Med
Line and C1NAHL search engines were used to identify 68
RCTs of dressings for venous ulcers. Two successive screens
were applied to select the final group of RCTs subject to
analysis: (1) elastic compression, as well as other modalities
of customary care, should be used in both arms of the RCT
and (2) outcomes should be objective and specifically detail
the proportion of wounds healed and the healing rate.
Thirty-three RCTs remained for analysis of valid outcomes
after the first screen. Thirteen more trials were subse-
quently eliminated, leaving 20 RCTs (29% of the original)
for final analysis.41 The 20 RCTs were analyzed for several
essential characteristics, many of which had been recom-
mended in an FDA document on wound care studies. A
priori calculation of sample size (40%), blinding of observ-
ers (35%), and outcome analysis by intention to treat (30%)
was observed in a low proportion of the studies. In contrast,
the majority employed baseline comparability, as demon-
strated by similar wound duration and area in the control
and experimental groups. The 20 RCTs were divided into
three groups based on the type of wound dressing used in
the experimental arm: (1) semi-occlusive dressings (SOD)
– eight studies, (2) growth factors (GF) – seven studies, and
(3) human skin equivalent (HSE) – five studies.
In over 50% of the RCTs, the wound was routinely
debrided, which has been shown to be an independent
factor promoting venous ulcer healing.39 While only 15%
of trials administered antibiotics, 52% used wound cleans-
ing. The preponderance of the studies used high degrees of
compression: four layer bandages were the most common
form of compression (7/20, 35%); studies using short
stretch bandages and class III stockings were comparable in
Table II. Dressing trials showing statistically improved ul
Dressing type
Patients (N)
and sites
Cont
(%
Semi-occlusive
Stacey42 113
Single site
Zinco
Paste
79%
Limova43 31
2 sites
Tegas
5%
Growth factor
DaCosta44 60 Placeb
19%
Mostow45 120
12 sites
Allevy
34%
Human skin equivalent
Falanga46 309
Multicenter
Tegap
48%number (4/20, 20%).In comparison with controls, five of the 20 RCTs
(25%) showed a statistically significant improvement in
the proportion of ulcers healed in the experimental
group (Table II). Stacey42 showed that wound healing
rates with Viscopaste (79%), a zinc oxide impregnated
bandage, were superior to either a zinc oxide impreg-
nated stockingette (59%) or a calcium alginate fiber
dressing (56%). Over an 8-week period, Limova43 re-
ported 59% of wounds healed with Tegasorb in compar-
ison with 15% treated with Duoderm, another hydrocol-
loid. Absorption of exudate and patient comfort was also
superior in the Tegasorb group. Among the three
growth factor studies, only one complex treatment reg-
imen, using granulocyte macrophage stimulating factor
(GMSF) administered by peri-ulcer injection44 was asso-
ciated with significantly improved healing rates in com-
parison with the control group (57% vs 19%). Although
improved wound healing with calcitonin vasoactive in-
testinal peptide34 has been claimed, re-evaluation of the
data by others failed to demonstrate statistical superior-
ity over Vaseline gauze. (personal communication,
Thomas F. O’Donnell, MD) Mostow45 compared colla-
gen derived from porcine small intestinal submucosa
(Oasis) with the semi-occlusive dressing, Allevyn.
Wounds healed in 55% of the Oasis group in comparison
with 34% in the Allevyn group. Finally, Falanga46 con-
ducted a multicenter trial with 309 participants treated
over a much longer period of 6 months. Using a complex
application schedule wherein five applications of Apligraf
(allogenic cultured human skin equivalent) were allowed
in the first 3 weeks of the trial if less than 50% of the
wound surface was covered by Apligraf, he observed a
63% healing rate in the experimental group vs a 49%
healing rate in the control group (Tegapore film dressing
and Unna’s boot). It should be noted that only two of
the trials reported ulcer recurrence during very limited
follow-up and neither showed an improvement over
ealing
essing
ed)
Experimental dressing
(% healed)
Study length
(wks)
ge
Calcium alginate 56%
Zincoxide stockinette
(59%)
36
DuoDerm
15%
8
. gauze Perilesional injection
of GMS stimulating
factor 57%
13
Porcine collagen S I S
55%
12
Apligraf
63%
24cer h
rol dr
heal
xide
banda
orb
o inj
n
orecontrols.
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plexity of application, ability to handle wound drainage,
and requirements for a special wound base. Certainly
cost, proportion of wounds healed, and time to healing
are other important factors in selection of a dressing. The
physician should employ the wound dressing which is
easiest to apply, and which is also associated with the best
drainage control and reduction of pain. Although some
modern dressings have an additive effect to compression
in promoting wound healing, more studies are needed. It
is also important to note that contact sensitivity from
ointments, creams, and dressings is a common feature in
leg ulcers.
Drug treatment of chronic venous insufficiency and
venous ulceration
Drugs are widely used in the management of chronic
venous insufficiency and venous ulceration. Unfortunately,
although much has been reported regarding alterations in
the microcirculation that give rise to leg ulceration,47 the
crucial steps that might be amenable to modification by
pharmacotherapy remain unknown.
When appropriately applied, traditional surgical tech-
niques and sclerotherapy work well in the management of
superficial venous disease.48 More recent techniques, such
as radio-frequency ablation, endovenous laser treatment,
and ultrasound guided foam sclerotherapy, may also have
advantages in the management of varicose veins. There is
little role for systemic drug treatment in such situations,
and no drug has yet been identified that will resolve valvular
incompetence. However, drugs are commonly used for
some of the milder symptoms attributed to superficial
venous incompetence, including aching, itching, and feel-
ings of swelling. “Phlebotonic” drugs are commonly used
in southern European countries where compression stock-
ings are less popular.
However, theremight be considerable advantage to the
use of effective drug treatments in the management of deep
venous incompetence. There is no widely used method of
restoring competence to damaged valves. Surgical tech-
niques for achieving this are well known but have limited
efficacy and scope. As discussed above, the use of high levels
of compression (45 mm Hg at the ankle) can achieve rapid
ulcer healing49 and should remain the standard treatment
in patients with deep venous incompetence once superficial
venous reflux has been corrected. Advances in the pharma-
cological treatment of venous leg ulcers have been limited
and as yet, no drug has been shown to achieve the same
level of healing as high levels of compression. The only oral
drugs that have been shown to have efficacy are pentoxifyl-
line and micronized purified flavonoid fraction (MPFF).
However, the development of drugs that could be used as
an adjuvant to compression is highly desirable.
Plant extracts, as well as a small number of synthetic
drugs, have been used to address the symptoms of venous
disease. This group includes hydroxyrutosides, diosmin,
and herperidine, all of which are flavonoids. Aescin, acompound present in many proprietary medications, has
also been widely used.
Diosmin is poorly absorbed from the GI tract and its
availability has been enhanced by micronization, a process
that reduces the drug to very small particles. Laurent inves-
tigated MPFF50 and demonstrated efficacy in reducing
symptoms (aching, itching, feeling of swelling) as well as
ankle edema. MPFF has been studied more recently for its
effects on venous leg ulcer healing. A meta-analysis of five
prospective, randomized, controlled studies included 723
patients with venous ulcers.51 Patients were treated with
compression bandaging and local wound care in all cases.
In two studies, MPFF was compared with placebo and in
three studies MPFF was compared with standard treatment
alone. At 6 months, the odds of ulcer healing was 32%
better in patients treated with adjunctive MPFF than in
those managed by conventional therapy alone. The primary
benefit of MPFF was seen in ulcers between 5 and 10 cm2
in area and in those present for 6 to 12 months. In combi-
nation with compression, MPFF may be a useful drug in
countries where it is licensed. At present, it is available in
some European, Asian, and South American countries but
not in the United Kingdom or the United States.
Pentoxifylline has been used with moderate success in
the treatment of claudication. Its mechanism of action is
probably through inhibition of cytokine-mediated neutro-
phil activation.52 Its efficacy in healing venous leg ulcers has
been reported in a meta-analysis of nine trials enrolling 572
adults.53 Pentoxifylline plus compression is more effective
than placebo plus compression (relative risk of healing with
pentoxifylline 1.30). This drug is widely available and could
be considered as an adjuvant to compression in patients
with venous leg ulceration.
Prostaglandin E1 is among the drugs that might influ-
ence inflammation, considered to be one of the primary
mechanisms leading to leg ulceration. Prostaglandin E1
(PGE1) has a number of profound effects on the microcir-
culation, including reduction of white cell activation, plate-
let aggregation inhibition, small vessel vasodilatation, and
reduction of vessel wall cholesterol levels. The results of a
randomized, placebo-controlled, single blind study 87 pa-
tients with venous leg ulcers have recently been reported.54
Patients were treated with compression bandaging and
conventional wound management in addition to a 20-day
infusion of prostaglandin E1 analogue (Prostavasin, Schwarz
Pharma, Monheim, Germany) or placebo. After 4 months,
all ulcers were healed in the active treatment group but only
32 of 38 in the placebo group. Unfortunately, despite its
efficacy, the requirement for intravenous infusion of the
drug restricts it applicability.
A prostacyclin analogue (Ilosprost, Schering, Berlin,
Germany) has also been investigated for efficacy in healing
venous ulcers. Although topic application had no effect on
healing,55 it is possible that an alternative route of admin-
istration might be effective.
Sulodexide, a highly purified glycosaminoglycan, has
also been evaluated in the treatment of venous leg ulcers.56Patients (n  235) with leg ulcers were randomized to
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tion to standard wound care and compression bandaging.
The trial medication was given for 20 days by injection and
thereafter orally. At 2 months, 35% of ulcers in the active
treatment group and 21% in the placebo group had healed.
This drug is not widely available and use on the basis of one
positive clinical trial cannot be recommended without res-
ervation.
A number of other drugs used in the management of
leg ulcer, particularly topical or systemic antibiotics, have
not shown efficacy in healing ulcers. Since leg ulcers are
frequently host to a wide range of bacteria, it has been
common practice to treat them with antibiotics. However,
there is no evidence that the bacterial colonization, which is
invariably present, has any effect on the perpetuation of the
ulcer. Antibiotics are only appropriate when treating clini-
cally apparent infection.
Similarly, trials of the anabolic steroid stanozolol have
not demonstrated efficacy in leg ulcer healing. The throm-
boxane A2 receptor antagonist Ifetroban, a platelet antag-
onist, was investigated in a randomized double blind study,
but no effect was found.57 Aspirin has not been studied in
such detail, but there is no reliable evidence of benefit in
treating venous ulcers. Hydroxyrutosides, often used in
“phlebotonic” drugs to treat venous edema, have been
found to have no effect of venous leg ulcer healing.58
A wide range of topical medications has been used in
the management of venous leg ulcers. These include tissue
growth factors intended to promote wound healing. No
large-scale trials support the use of these drugs, although
small studies have apparently found some beneficial effects.
Several case series reported promising results with topical
and perilesional injections of granulocyte-macrophage col-
ony-stimulating factor (GM-CSF) and platelet derived
growth factor, human keratinocyte growth factor-2, and
hepatocyte growth factor have also been investigated.59
SURGICAL TREATMENT OF CHRONIC
VENOUS INSUFFICIENCY
Until 2003, the Cochrane group favored medical treat-
ment with agents such as pentoxyphylline and flavonoids
over surgical treatment. However, more recent evidence
suggests a significantly more important role for surgical
management. The role of surgery has become more secure
with the recent publication of a randomized trial compar-
ing surgery and compression with compression alone.48
The ESCHAR study evaluated 500 patients with ultra-
sound, allocating those with superficial reflux or combined
superficial and deep reflux to an arm including “simple
venous surgery.” Although the addition of surgery did not
affect 24-week healing rates, ulcer recurrence rates were
reduced from 28% to 12% at 12months. These numbers are
consistent with recurrence rates after operative intervention
for perforator incompetence60 and consistent with histori-
cal results for modified interventions addressing perforator
and axial incompetence.61-64 Ulcer recurrence rates ranged
average 9% to 10%. An analysis of independent factorspromoting recurrence has shown that venous reflux not
treated by surgery is an important factor in recurrence.
Local surgical procedures
Debridement allows the removal of necrotic tissue and
may promote formation of granulation tissue. Radical ex-
cision of the ulcer bed may also be considered, especially in
recalcitrant, long-standing ulcers. The fibrotic suprafascial
tissue, sometimes including the fascia, is excised and the
defect closed by skin grafts or free flaps. Any incompetent
perforators may be dissected at the same time.
Surgery to correct venous reflux
The vast majority of patients theoretically have one or
more sites of proximal reflux or obstruction that could
benefit from operative treatment.65 Many of these patients
can benefit from interventions directed towards an incom-
petent superficial venous system. Techniques for ablation of
saphenous vein reflux, including high ligation with strip-
ping, and endovenous thermal ablation are more thor-
oughly reviewed in the primary venous disease section of
this supplement. Foam sclerotherapy is also an excellent
method to obliterate incompetent segments of the large
and small saphenous vein, which is frequently followed by
accelerated healing of the ulcer.66
In a randomized controlled trial, superficial venous
surgery did not improve the healing rate of venous ulcers,
but could significantly reduce the 12-month rate of ulcer
recurrence.48 In a subgroup analysis of this study, it was
shown that superficial venous surgery might improve ve-
nous hemodynamics in legs with venous ulceration despite
co-existent deep reflux.67 Surgical correction of superficial
reflux may also abolish incompetence in some calf perfora-
tors and offer protection against developing new perforator
incompetence.
Deep venous valve reconstruction is performed in only
a few specialized centers. Unfortunately, the results are
better for primary deep venous incompetence than for
post-thrombotic syndrome.68 As discussed in the section of
primary venous disorders, internal valvuloplasty is the most
suitable technique for correcting primary deep venous in-
competence and is associated with approximately 70% free-
dom from ulcer recurrence at more than 5 years follow-
up.68-71 In contrast, axillary vein transfer72 is the mainstay
for reconstruction of a refluxing, post-thrombotic deep
venous system in which the valves are destroyed. Actuarial
ulcer healing rates have been variable, ranging from 40% to
65% at 5 years or longer. However, in the absence of
suitable alternatives, these are nevertheless significant re-
sults for a salvage procedure. Although Perrin70 noted a
high incidence of partial, and occasionally total thrombosis,
within a few weeks of transfer; Raju reported results similar
to those in “primary” disease. Ten-year actuarial ulcer
healing was 60% and patency 90% in a large series of
post-thrombotic patients.73
Despite appearances, axillary vein transfer is technically
more difficult than internal valvuloplasty. Proctored learn-
ing is essential for proficiency and special modifications
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cases.72 Successful reconstruction of the entire femoral
trijunction has been reported in 32 cases using one such
modification.
Surprisingly, valves in the post-thrombotic syndrome
are not universally destroyed. Some are preserved but be-
come “secondarily” incompetent due to wall station restric-
tion by perivenous and wall fibrosis extending some dis-
tance from the actual thrombotic segment. This may
explain the well-documented observation that valves re-
mote from the thrombotic segmentmay eventually become
incompetent. Regardless, such secondarily incompetent
valves are amenable to direct repair without resorting to
axillary vein transfer. Preoperative identification of second-
arily incompetent valves by contrast venography or duplex
is unreliable. Initial adventitial dissection to expose the
valve attachment lines on the mural surface is an essential
first step in all valvuloplasty techniques. However, very
careful dissection of the thicker post-thrombotic adventitia
is required to determine whether a direct repair is feasible.
The presence of the lines in their entirety indicates a repair-
able valve; their absence suggests the need for axillary valve
transfer. Venotomy is not required and time need not be
wasted in a futile search for nonexistent valve cusps.69-83
Eriksson75 pointed out the importance of profunda
repair in post-thrombotic patients. The femoral vein is
totally occluded with corresponding dilation of the pro-
funda femoris vein in approximately 10% of post-throm-
botic patients. The course and caliber of the profunda
collateral may be so close to normal anatomy that it can be
easily missed. The profunda valve apparatus is dilated,
incompetent, and may be associated with recalcitrant ul-
cers. The valve is amenable to direct valvuloplasty with
excellent long-term results.
Surgery to correct perforating vein incompetence
Despite evidence that surgically uncorrected venous
reflux is an important factor in recurrence,84 the role of
procedures addressing perforator incompetence remains
controversial. Surgery of incompetent perforators has dem-
onstrated promising results, especially in cases with intact
deep veins.67 However, there remain concerns that new
incompetent perforators continue to develop over time.
Most reports have not consistently used the most recent
iteration of CEAP8 to evaluate initial disease severity, the
extent of disordered anatomy and physiology, and out-
comes after the diverse interventions available to treat
perforator incompetence. Randomized controlled trials
will ultimately be needed to clarify the role of perforator
surgery in the management of venous leg ulcers.
The surgical options for treating incompetent perforat-
ing veins include open subfascial interruptions; the rarely
used classic Linton approach; subfascial endoscopic perfo-
rator surgery (SEPS) with or without axial vein ablation;
extrafascial perforator interruptions including extrafascial
spot ligations; and shearing procedures for distal venous
ulcers. These procedures are sometimes used in combina-
tion.There have also been promising reports using foam
sclerotherapy in the treatment of incompetent perforat-
ing veins. The use of foam achieves an important treat-
ment goal - local diversion of elevated venous pressure
and reflux from the ulcerated area. However, the success
of this approach likely depends on concurrent reduction
of global reflux and sustained venous hypertension
through proximal surgical procedures. In a retrospective
study of 116 patients treated with foam sclerotherapy,66
ulcers healed in 83% of patients after 6 months. Bergan85
has summarized the sclerotherapy results in class 4-6
disease and proposed guidelines for the use of sclerosants
in the United States. These methods require careful
prospective study as well.
MANAGEMENT OF CHRONIC VENOUS
OBSTRUCTION
Clinical presentation
Iliac venous outflow obstruction appears to play a more
important role in chronic venous insufficiency than previ-
ously understood.79 Obstruction of the iliocaval venous
segment, the common path for the lower extremity venous
outflow, appears to be more symptomatic than more distal
segmental occlusions. Patients with venous occlusion have
leg swelling and experience exercise-induced pain in the
thigh, and occasionally the calf muscles. Such venous clau-
dication is described as a ”bursting” pain that is relieved by
rest and elevation of the legs. A syndrome of spinal claudi-
cation, due to spinal compression by venous collaterals, has
also been rarely described. Significant deep venous obstruc-
tion causes distended varicose veins even in the supine
patient; suprapubic and abdominal wall collaterals also
develop in patients with pelvic venous occlusion. Bleeding
from high-pressure varicosities is not infrequent and venous
congestion occasionally results in hyperhydrosis and signif-
icant fluid loss through the skin. Obstruction following
acute deep venous thrombosis is frequently associated with
distal post-thrombotic venous valvular incompetence, lead-
ing to skin changes and venous ulceration.
Etiology and clinical importance of venous
obstruction
Obstruction is most commonly due to absent or poor
recanalization following an episode of acute deep venous
thrombosis (DVT). Only 20% to 30% of iliac vein thrombi
completely recanalize with anticoagulation alone, while the
remaining veins develop obstruction with variable collater-
alization.86,87 Obstruction occurs in association with reflux
in 55% of symptomatic patients and this combination leads
to the higher ambulatory venous pressures and more severe
symptoms then either condition alone. Obstruction is the
principal cause of symptoms in approximately one-third of
post-thrombotic limbs.87,88
The importance and frequency of “primary,” non-
thrombotic iliac vein obstruction (May-Thurner syndrome
or iliac vein compression syndrome) is less commonly ap-
preciated.89-91 Among more than 1000 obstructive limbs
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proximately 40% had non-thrombotic occlusion (defined
by an absent history of DVT and no venographic or ultra-
sound findings indicating previous DVT). Obstruction typ-
ically is due to compression, sometimes with intraluminal
band or web formation, at the point where the right com-
mon iliac artery crosses the proximal left common iliac
vein.92 Although this lesion is classically reported in the left
iliac vein in young females, it is not uncommon in elderly
patients and males and may also involve the right limb.
Compression involves both the common and external iliac
veins in at least 15% of patients.93 Other have reported that
intraluminal iliac vein lesions and external compressionmay
be present in 14-30% and 88%, of the general population,
respectively.91,94 The incidence is probably higher in symp-
tomatic patients. One may speculate that such lesions are
clinically silent until other components of the venous cir-
culation fail and the extremity becomes decompensated.
The possibility that limbs with “primary”, non-throm-
botic disease had an isolated, subclinical iliac vein throm-
bosis initiated at the vessel crossing that propagated distally
into the external iliac vein cannot be excluded. On the
other hand, limbs with obvious post-thrombotic disease
may have had an underlying iliac vein compression leading
to iliofemoral vein thrombosis. It has also been shown that
recanalization after acute iliofemoral DVT is worse when an
external compression is present.95 Regardless of the under-
lying events, it is clear that patients complaining of leg pain
and swelling and without a history of DVT or other venous
disease may have isolated iliac vein obstruction.
Less common causes of chronic iliocaval obstruction
include benign or malignant tumors, retroperitoneal
fibrosis, iatrogenic injury, irradiation, cysts, and aneu-
rysms. Signs and symptoms of an underlying malignancy
(weight loss, malaise, fatigue, low grade fever) or retro-
peritoneal fibrosis (low back pain, hydronephrosis)
should be sought in patients presenting with iliofemoral
venous obstruction.
Diagnosis and selection of patients
The investigation of the patients with suspected venous
obstruction begins with a thorough history and physical
examination followed by detailed lower extremity venous
duplex scanning evaluating both obstruction and valvular
incompetence. Thrombophilic states should be excluded in
all patients with a previous episode of DVT. Pelvic imaging
studies (computed tomography or magnetic resonance im-
aging) should be obtained to exclude malignancy, benign
tumors, retroperitoneal fibrosis, and other etiologies.
Computed tomography can also confirm compression of
the left iliac vein by the overlying right common iliac artery
(May-Thurner syndrome). Venous functional studies, such
as air or strain gauge plethysmography, may establish the
presence of outflow obstruction and aids in assessing post-
operative improvement. Ascending contrast venography,
with direct venous pressure measurements, will delineate
the anatomy and despite the absence of a uniform defini-
tion, can suggest a hemodynamically significant obstruc-tion. In the absence of reflux, ambulatory venous pressure
measurements are usually normal, although a resting arm-
foot pressure differential of 5 mmHg or greater is consid-
ered evidence for significant obstruction. For purposes of
provocative testing, exercise consists of 10 dorsiflexions of
the ankles or 20 isometric contractions of the calf.
Unfortunately, the definition of hemodynamically sig-
nificant venous stenosis remains obscure and there are no
reliable tests to confirm the presence of such a lesion.96
Although tests suggesting obstruction indicate the need for
further investigation, a negative test does not exclude its
presence. Absence of a “gold standard” is a major obstacle
in evaluating the importance of chronic outflow obstruc-
tion, selecting limbs for treatment, and evaluating out-
come. At present, the diagnosis of outflow obstruction
largely depends on anatomic rather than hemodynamic
criteria. Ascending or antegrade transfemoral venography
(optimally performed with oblique projections) is the stan-
dard method of imaging the venous outflow tract and may
disclose the site of obstruction and the presence of collat-
erals. However, intravascular ultrasound (IVUS) is superior
to venography in estimating the morphological degree and
extent of iliac vein stenosis and visualizing details of intralu-
minal lesions.97 Iliocaval obstruction and associated abnor-
malities can also be detected by magnetic resonance venog-
raphy (MRV) and spiral computed tomographic (CT)
venography, which may replace invasive studies in the
future.98,99
The appropriate diagnosis of venous obstruction re-
quires a high degree of suspicion and a low threshold for
extending investigation beyond duplex ultrasound evalua-
tion of the lower extremity. Especially targeted patients are
those with clinical features (especially pain) out of propor-
tion to detectable pathology, patients lacking another ex-
planation for their symptoms, and patients with previous
deep venous thrombosis.
Symptomatic patients with a suspicion of obstruction,
with or without collaterals on ultrasound or transfemoral
venography, and/or positive invasive or noninvasive tests
for outflow obstruction warrant further study.
Endovascular reconstruction for chronic iliac vein and
inferior vena cava obstruction
Iliocaval venoplasty and stenting has emerged as the
“method of choice” in relieving proximal iliofemoral ob-
struction. As discussed above, the selection of patients for
treatment is hampered by the lack of objective hemody-
namic tests for venous obstruction and currently must be
based on clinical signs and symptoms in conjunction with
anatomic investigations. However, many experts believe
patients with iliocaval stenosis of more than 50% on IVUS
to be candidates for intervention.100
The technical details of the procedure have been previ-
ously described.101 Although percutaneous stenting is a
minimally invasive procedure, attention to detail is impor-
tant to ensure a satisfactory result. Important points of the
procedure include:
s of th
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recoil after venoplasty alone and should be considered
standard.
● Ultrasound guided puncture of the ipsilateral femoral
vein below the suspected obstruction should be rou-
tinely used.
● IVUS is invaluable, both as a diagnostic and therapeu-
tic tool to direct stent placement.
● When treating stenosis close to the common iliac
confluence, especially when using Wallstents, place
stents well into the IVC to avoid distal migration.
● A large stent (14 to 16 mm diameter) is recom-
mended. In contrast to arteries, most veins will tolerate
extensive dilation without clinical rupture.
● The entire obstruction delineated by IVUS should be
covered to decrease the risk of re-stenosis.
The mortality following endovenous stenting is nil and
the morbidity is 1%. Cumulative secondary patency rates
are approximately 90% at 4 to 6 years and late occlusions are
rare.102,103 A number of patients have been followed for 5
years or more without precipitous deterioration of stent
patency or clinical efficacy. However, limbs with chronic
post-thrombotic disease fare significantly worse after stent-
ing than those with non-thrombotic disease (primary, as-
sisted-primary and secondary cumulative patency rates of
65%, 85%, and 88%, and 89%, 100% and 100% at 36
months, respectively).103,104 Early occlusion was more
common in post-thrombotic patients with thrombophilia
and extensive iliofemoral occlusion or tight, non-yielding
stenoses (especially when extending below the inguinal
ligament). Recanalized limbs have a secondary patency of
76% at 24 months.105 In-stent restenosis of greater than
50% is infrequent and occurs more commonly in post-
thrombotic than non-thrombotic limbs (23% and 4%, re-
spectively).100
Despite the absence of objective hemodynamic out-
come measures, the clinical efficacy of iliofemoral venous
Table III. Results of femoro-femoral venous bypass
Author Year
No. of
limbs
Follow-up
(y)
Postoperative
imaging (%)
Palma 1960 8 up to 3 13
Dale 1979 48 up to 12 N/A
May 1981 66 N/A N/A
Dale 1983 56 N/A N/A
Husni 1983 85 0.5  15 N/A
Halliday 1985 47 up to 18 72
Danza 1991 27 N/A N/A
AbuRahma 1991 24 5.5 100
Gruss 1997 19 N/A N/A
32 N/A N/A
Jost 2001 18 2
3
Adopted from Gloviczki P, Cho JS. Surgical treatment of chronic occlusion
surgery, 6th edition. Philadelphia: Elsevier 2005:2303-2066.108stenting is supported by impressive relief of pain and swell-ing and high rates of ulcer healing. Objectively docu-
mented swelling is completely relieved in approximately
one-third of limbs and is significantly improved in others.
About 50% of patients have complete relief of pain follow-
ing stenting. Despite the presence of untreated reflux in
many limbs, approximately half of ulcerated legs will heal,
and stay healed for up to 2 years, following iliac vein stent
placement.103,104 Median venous clinical severity and dis-
ability scores also significantly improve (8.5 to 2 and 2 to 0,
respectively).102
Surgical reconstruction for large vein occlusions
The success of endovascular procedures for venous
obstruction has diminished the role of bypass procedures in
recent years.106,107 Early recognition and aggressive treat-
ment of venous obstructions with catheter directed throm-
bolysis, mechanical venous thrombectomy, balloon angio-
plasty, and stents have been effective and durable with
satisfactory early and midterm results. Bypass surgery is
now largely limited to stent failures, both early and late, and
long total occlusions, which appear to have a poorer re-
sult.108,109 Patients requiring resection for malignancy also
continue to require surgical reconstruction of critical veins
such as the inferior and superior vena cava.110
Femoro-femoral venous bypass (Palma procedure).
First described by Palma and Esperon, the Palma procedure
remains a useful technique for venous reconstruction in
patients with unilateral iliac vein obstruction who are not
candidates for or who have failed previous endovascular
procedures.109 The operation requires a normal contralat-
eral iliofemoral venous system to assure venous drainage.
The Palma procedure uses the contralateral great saphe-
nous vein as a bypass conduit. As long-term outcomewith the
use varicose saphenous veins and veins smaller than 4 mm are
poor, preoperative duplex imaging is recommended. The
saphenous vein is harvested using the endoscopic technique or
a few small skin incisions. After ligation and division of all
Patency rate (%)
Clinical
improvement (%)
Graft
material
N/A 88 Vein
N/A 77 Vein
73 N/A Vein
N/A 80 Vein
70 74 Vein (n  83)
PTFE (n  2)
75 (5-y cumulative) 89 Vein
N/A 81 Vein
75 (7-y cumulative) 63 Vein
71 82 overall Vein
85 PTFE
imary 77; secondary 83 Vein
0 PTFE
e iliac veins and the inferior vena cava. In: Rutherford RB, editor. VascularPrtributaries, the graft is distended with heparinized papaverine
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bic, subcutaneous position, where it is anastomosed to the
common femoral vein. Excision of intraluminal post-throm-
botic fibrous bands following femoral venotomy (endophle-
bectomy) may be needed. When suitable autologous conduit
is not available, an 8 or 10-mm, externally supported ex-
panded polytetrafluoroethylene (ePTFE) graft is the best al-
ternative. A temporary arteriovenous fistula can be placed to
improve flow and to aid patency. A large tributary of the
ipsilateral great saphenous vein or the transected great saphe-
nous vein can be anastomosed in an end-to-side fashion to the
proximal superficial femoral artery. In patients with vein graft,
this fistula is taken down at 3 months. In those with ePTFE
grafts, the fistula should be left as long as possible in an
asymptomatic patient.
Analysis of 412 operations published in nine series
revealed clinical improvement in 63% to 89% of patients
(Table III). Crude patency rates ranged between 70% and
85%, but follow-up periods were variable and objective
graft assessment with imaging was rarely routinely per-
formed. Results were better in patients who had regular
surveillance and in those with a temporary arteriovenous
fistula, with minimal distal disease, and with non-throm-
botic disease (Fig 1). At least one center109 reported 4-year
patency rates as high as 83% for Palma grafts.
Prosthetic femorocaval or iliocaval bypass. Ana-
tomic in-line iliac or iliocaval reconstruction can be per-
formed for (1) unilateral disease when autologous conduit
Fig 1. Venograms showing patent left to right cross-femoral sa-
phenous vein graft 6 months after Palma procedure. From Jost CJ,
Gloviczki P, Cherry KJ,McKusickMA,HarmsenWS, Jenkins GD,
Bower TC. Surgical reconstructions of iliofemoral veins and the
inferior vena cava for nonmalignant occlusive disease. J Vasc Surg
2001:33:320-8, with permission.109for a suprapubic graft is not available or (2) bilateral iliac,iliocaval, or inferior vena caval occlusion. In addition to
failed endovascular treatment, extensive venous thrombosis
(frequently following placement of a vena caval clip), tu-
mors, and retroperitoneal fibrosis unresponsive to nonop-
erative therapy are potential indications.
The femoral vessels are exposed at the groin through a
vertical incision, the iliac vein and the distal inferior vena
cava (IVC) through oblique flank incisions. The IVC at the
level of the renal veins is best exposed through a midline or
a right subcostal incision. If the IVC alone is reconstructed,
an externally supported 16- to 22-mm PTFE graft is appro-
priate. The iliocaval segment is usually reconstructed with a
14-mm graft. An arteriovenous fistula is constructed for
femorocaval or long iliocaval bypasses. The fistula is main-
tained as long as possible, a minimum of 3 months. Life-
long anticoagulation is recommended.
Experience with femorocaval and iliocaval bypass is
limited, but 2-year primary and secondary patency rates of
37% and 54% have been reported108,109 (Fig 2). In an
unpublished series of 56 patients undergoing a variety of
prosthetic reconstructions for iliac vein occlusion, Sottiurai
reported a 93% 1-year patency rate.
Endophlebectomy. Excision of the recanalized, orga-
nized thrombus, together with any newly formed intima, is
a procedure that can be performed either alone for localized
venous obstruction or combined with intraoperative il-
iofemoral stenting or bypass procedures. The procedure
has long been combined with deep venous valve recon-
structions, but it can be equally effective for venous ob-
struction alone. Closure of the vein is usually performed
Fig 2. Patent left femorocaval PTFE bypass 11.7 years after sur-
gery. From Jost CJ, Gloviczki P, Cherry KJ, McKusick MA,
Harmsen WS, Jenkins GD, Bower TC. Surgical reconstructions of
iliofemoral veins and the inferior vena cava for nonmalignant
occlusive disease. J Vasc Surg 2001:33:320-8, with permission.109with a vein or bovine pericardial patch. Puggioni111 re-
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patent at 8 months. Long-term patency in a larger series of
patients has not yet been reported.
Inferior vena cava reconstruction combined with
excision of malignant tumors. Primary venous leiomyo-
sarcomas or secondary tumors invading the vena cava are
the most frequent indications for reconstruction. The pri-
mary tumor can involve the liver, the retroperitoneum, or
the kidneys. Excellent patency of the suprarenal or infrare-
nal IVC can be achieved with externally supported PTFE
grafts. The renal veins can also be reconstructed using short
PTFE grafts. For tumors partially invading the venous wall,
lateral excision and venography with or without PTFE or
bovine pericardial patches are options. Patients with renal
cancer frequently have floating tumor thrombus in the IVC
that can be removed without circumferential reconstruc-
tion of the cava. Tumors that extend up to the right atrium
need extracorporeal circulation for safe removal of the
tumor thrombus.
Bower and Nagorney110 reported large experience with
tumor resection and inferior vena cava reconstruction using
PTFE grafts. Of 27 caval reconstructions, only two graft
occlusions, at 7 months and 6 years, were noted. Twenty-five
grafts remained patent after an average follow-up of 2 years.
Reconstruction of the superior vena cava. Surgical
reconstruction is indicated in symptomatic, good risk pa-
tients with nonmalignant disease who have failed or are not
candidates for endovascular treatment. Etiologies of severe
superior vena cava (SVC) obstruction include mediastinal
fibrosis and extensive venous thrombosis after central ve-
nous instrumentation.
A chest CT is essential to exclude an underlying tumor
or mediastinal fibrosis. Bilateral arm venography provides a
road map for reconstruction, while duplex scanning of the
internal jugular veins is useful in assessing inflow for a
central bypass.107
Reconstruction is performed through a median ster-
notomy, with extension of the skin incision into the neck if
anastomosis to the internal jugular vein is required. The
central anastomosis is usually done to the SVC, if there is an
adequate patent segment above the atrium, or to the right
atrial appendage. Many experts consider a spiral saphenous
vein graft to be the conduit of choice for SVC reconstruc-
tion, although the femoral vein is also a good conduit in
selected patients. Externally supported PTFE is also suit-
able in this location; best results are achieved with short,
large diameter grafts (12 mm to 16 mm ).
Superior vena cava grafts of different types have an 80%
5-year patency rate (Fig 3). Published secondary patency
rates of spiral saphenous vein grafts at 5 years are 90%.110
Patency rates with femoral vein and PTFE grafts have been
somewhat inferior to this. Secondary procedures, such as
angioplasty or stenting may be required to maintain and
prolong patency. Regular follow-up with magnetic reso-
nance, computed tomography, or contrast venography is
warranted.ARTIFICIAL VENOUS VALVES
An artificial venous valve is needed to treat chronic deep
venous insufficiency (DVI) after other options have failed.
The typical patient has post-thrombotic valvular insuffi-
ciency with recalcitrant or recurrent venous ulcers resistant
to standard medical and surgical therapy. Options for arti-
ficial venous valves fall into two categories: Scaffolds seek-
ing incorporation as self and scaffolds identified as self.
Valve cusps made of autogenous vein are the only currently
available substitutes with at least preliminary data support-
ing their use. Although there is clearly a clinical need,
nonautogenous off-the-shelf venous valve substitutes have
either failed initial clinical evaluation or remain under de-
velopment.
Scaffolds seeking incorporation as self
Several approaches to construction of an artificial valve
have been abandoned after discouraging results in animal
studies. Among 14 fresh valved vein allografts implanted in
dogs, only 7% remained patent in a 4-week study.112 Sim-
ilar results were obtained with bicuspid valve xenografts
created from glutaraldehyde-fixed human umbilical veins
supported by an aluminum mandrel.113 All 10 canine trans-
plants thrombosed within three days. Ten canine implants
of a liquid pellethane bicuspid valve supported by the same
aluminum mandrel similarly thrombosed within 8 days.113
In other cases, the animal or associated studies left some
hope for this approach. Platinum or pyrite-carbon covered
titanium center-hinged bileaflet valves implanted in the dog
femoral vein had 100% patency and competency at 3
months.114 However, extensive neointimal overgrowth re-
sulted in valve failure at 2 years.115 It is possible that modifi-
cations could extend valve life. Allograft valve decellulariza-
tion could provide a transplant devoid of donor cells.
Cryopreserved, decellularized allografts implanted as arterio-
venous fistulae (AVF) have functioned well and incited little
Fig 3. Patency of superior vena cava bypasses in 29 patients.
From Kalra M, Gloviczki P, Andrews JC, Cherry KJ, Jr., Bower
TC, Panneton JM, et al. Open surgical and endovascular treatment
of superior vena cava syndrome caused by nonmalignant disease. J
Vasc Surg 2003;38:215-23, with permission.107antigenic response.116 However, use of decellularized allo-
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without anticoagulation.117 Despite the failure of decellular-
ized allografts in animal models, the clinical experience sug-
gests the need for further study. Finally, rehydrated lyophi-
lized valved veins mechanically respond similar to native
valves.118 Such valves can withstand greater than 350 mm Hg
retrograde pressure without reflux and closure time is an
acceptable 0.31 0.03 seconds. This allograft remains un-
tested in vitro as a potential venous valve substitute.
Glutaraldehyde preserved allografts supported by a dis-
tal AVF remained patent (80%) but rarely competent (25%)
in a 7-week canine study.119 Glutaraldehyde-preserved bo-
vine cardiac valves function well clinically and the technol-
ogy exists to similarly preserve bovine venous valves of a size
appropriate for human use. A glutaraldehyde-preserved
bovine valve-containing vein has been percutaneously
placed in a swine model. In three surviving animals, the
valves remained patent and competent.120 However, initial
results from an unpublished clinical trial using a similar
construct were discouraging and led to development of a
streamlined design. The new design likely failed to solve
clinical concerns since the parent company no longer exists.
A bioprosthetic, bicuspid stent-based venous valve has
also been developed and percutaneously deployed in the
external jugular vein of sheep.121 The valve is made of
processed small intestinal submucosa (SIS – a collagen
skeleton with growth factors) stretched over a square metal
frame with a slit cut to form the valve opening. The valve is
relatively resistant to thrombosis and becomes repopulated
with recipient endothelial cells.121,122 Although patency
and competency of this valve was 88%, tilting led to valve
malfunction or occlusion in three animals.121 Subsequent
modifications have been designed to ensure centering of
the valve, improve valve hemodynamics, and prevent cusp
thickening.123 Development of this valve is ongoing
(Cook, Inc, Bloomington, Ind) and early clinical studies
are being performed outside of the United States.
A cryopreserved allograft valve utilizing standard cross
matching has reached clinical trials. Despite encouraging
preclinical canine studies,124 a multicenter feasibility study
suggested that low grade rejection phenomenon damaged
the allogenic femoral valves yielding primary patency and
competency rates of only 67% and 56%, respectively.125 A
2-year clinical study reported a disappointing 27% patency
and competency rate.126
Cryopreserved femoral valved veins (cryovalve) are cur-
rently available (CryoLife, Inc, Kennesaw, Ga). During
testing, this valve remained competent to at least 125 mm
Hg of retrograde pressure. Date suggests that primary
valvuloplasty may be required after thawing to ensure initial
competence and this valve does fail with time.125,126 It may
be possible to temper the rejection issues associated with
this valve, but this has not been evaluated in clinical trials.
Scaffolds identified as self
Valves created by intussuscepting an autogenous vein
into itself and forming a bicuspid valve with sutures 180
degrees apart have been evaluated in animal studies.127,128In experimental studies, short-term patency and compe-
tency at physiologic pressures were excellent.127 When
transplanted into the femoral vein of a canine model of
chronic deep venous insufficiency, a less hemodynamically
responsive valve was suggested by a modest improvement
in the 90% venous refill time but not the venous filling
time.127 Investigation of a modified valve, with thinner
cusps, in a canine model showed that the valve opened
rapidly with minimal pressure, closed at a pressure of 3 to 5
cm of water and could withstand physiologic hydrostatic
pressure without reflux.129 However, a thin layer of throm-
bus formed along the cusp wall without anticoagulation,
resulting in valve incompetence. Although a possible sub-
stitute valve, there remain concerns regarding optimal
function and the risk of thrombosis.
Repopulating a decellularized valved vein allograft with
donor smooth muscle and endothelial cells would make a
transplant much like an autogenous valve. In a sheep
model, the seeded allograft was transplanted into the exter-
nal jugular vein of the donor. Without long-term anticoag-
ulation, 9 of 12 seeded allograft transplants were patent and
competent at 12 weeks. One transplant occluded and two
valves were frozen by neointimal ingrowth.117 These allo-
grafts did perform much better than unseeded allografts,
which universally failed; but not as well as eight autografts,
which were all patent and competent.
Clinical studies have also evaluated the use of autoge-
nous venous tissue to create venous valves. Raju reported
good results in a small series of patients who underwent “de
novo” valve reconstruction procedures.130 Using autoge-
nous vein from various locations and after trimming the
adventitia and part of the media, semi-lunar cusps were
fashioned and sutured into the recipient vein with the
non-endothelial surface directed toward the lumen to de-
crease thrombotic risk.
Plagnol131 fashioned a bicuspid valve by invaginating a
stump of the long saphenous vein into the femoral vein.
Nineteen of 20 such reconstructions were patent and compe-
tent at a mean of 10 months. One valve demonstrated reflux
because of insufficient valve length. Although a potential
concern, problems with invagination of an adventitial surface
into the venous lumen were not substantiated in this report.
Others have reported the creation of bicuspid or monocusp
valves by dissecting the intimal/medial wall of thickened
post-thrombotic veins to form cusps. The initial seven cases 132
were sufficiently successful to warrant continued study and a
total of eighteen venous valves constructed in the post-throm-
botic deep venous system of 16 patients with recurrent or
non-healing venous ulcers have now been reported.133 These
patients were anticoagulated for 6 months. At an average 22
months, 83% of the valves remained primarily patent with
improved duplex and air plethysmographic findings. Early
thrombosis below the valve occurred in two patients and there
was one late occlusion after beginning oral contraceptives.
This technique appears promisingbut is as yet unsubstantiated
by other investigators.
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